Our comprehensive CBRN portfolio provides immediate,
reliable, and easy-to-use first-line-of-defense medical
treatments against chemical warfare agents for government
agencies, military forces, and civilian populations
Our one-of-its-kind FDA-approved midazolam autoinjector enables
immediate, safe, and effective treatment for status epilepticus in combat casualty care and in pre-hospital settings.
Rafa is developing a high dose naloxone autoinjector to treat opioid overdose.
The naloxone autoinjector can act as a medical countermeasure
against opioids used as chemical weapons.
Naloxone is designed to reverse or minimize the effects of opioids,
specifically used to counter respiratory depression during an opioid overdose.
The widespread impact of opioids, particularly fentanyl, is evident in the ongoing opioid epidemic in the United States, presenting a significant counternarcotic challenge. Furthermore, there has been growing discussion, including congressional interest, on whether fentanyl should be classified as a weapon of mass destruction (WMD) and if the U.S. Government’s chemical defense efforts should prioritize appropriate countermeasures.
Rafa is developing an asoxime (HI-6) autoinjector for protection against five key nerve agents.
The new autoinjector will feature larger injection volumes and is designed in collaboration with a renowned autoinjector manufacturer.
Asoxime can reactivate AChE inhibited by nerve agents and when given with atropine, demonstrated an ability to assure the survival of experimental animals poisoned with multiple lethal doses of nerve agents.
Rafa is developing a scopolamine autoinjector, repurposing scopolamine hydrobromide as a centrally-acting adjunct therapy that would be administered in conjunction with known antidotes such as atropine.
Scopolamine readily crosses the blood-brain barrier and acts as a competitive antagonist at muscarinic acetylcholine receptors. It is intended to improve survivability and medical treatment outcomes against the central symptoms of current and emerging nerve agent threats.
